Figure 5. Effect of VEGF and Bevacizumab on proliferation of BCE cells. A, B: Effect of different concentrations (0.1–2 mg/ml) of Bevacizumab on proliferation of BCE cells. Increasing concentrations of Bevacizumab (1–2 mg/ml) produce a significant decrease in cell proliferation rates compared to controls. VEGF does not significantly change BCE proliferation rates as compared to controls. Cell proliferation was determined by the WST-1 assay and automated cell counting. Proliferation rates are expressed as percentages of control values. Proliferation rates under serum-starved conditions were considered as positive controls; BEV (Bevacizumab); V (vascular endothelial growth factor; VEGF). * Indicates a significant decrease as compared to control (p<0.05).